CA-INFOGAIN
4.1.2022 06:39:11 CET | Business Wire | Press release
Infogain, a Silicon Valley-based global leader in human-centered digital platform engineering services, has appointed Dayapatra Nevatia as President and Chief Operating Officer, responsible for global operations. Reporting to CEO Ayan Mukerji, he will support and execute Infogain’s strategy of combining cloud, experience, and AI to build innovative human-centered digital solutions for our customers.
Nevatia is a well-respected IT industry veteran with close to three decades of experience in client value creation and delivery, incubating new business verticals, managing large P&Ls, and leading culturally diverse global organizations with more than 100,000 global team members. In his most recent role as Mindtree’s Executive Director and Chief Operating Officer, he was responsible for designing, planning, and implementing business strategies and operating plans that align with the company’s vision and long-term goals.
Prior to Mindtree, Nevatia served in senior leadership roles at Accenture for many years. As Managing Director and Director of Delivery for Advanced Technology Centres in India for Accenture, he was part of their Indian executive leadership team, delivering programs in system integration, application outsourcing, infrastructure, digital, and security services across different industry groups.
Infogain CEO Ayan Mukerji said, “Dayapatra brings deep knowledge of managing growth and scale with a solid understanding of technology. Infogain will benefit from this expertise. His addition to our executive leadership team will also add a new perspective and enhance our ability to solve complex business challenges facing our customers today.”
Mukerji continued, “I’d also like to thank Eddie Chandhok for his 18 years of outstanding performance nurturing our organization’s growth. Eddie will stay on with the company and continue to drive Infogain’s M&A function, which is increasingly becoming more strategic as we continue to bring on new talent and integrate new global delivery locations.”
Dayapatra added, “I am excited to be joining a rapidly growing digital engineering company like Infogain, with futuristic leaders who are all-in, building platforms that drive our customers' business.”
Shashank Singh, Partner at Apax, which advises funds that are majority owners of Infogain, said, “Dayapatra’s impressive background and experience working with CEOs, CDOs, and CTOs of Fortune 100 companies make him a great fit for taking Infogain’s delivery and operations to the next level.”
Rohan Haldea, Partner at Apax, added, “This is another exciting step in Infogain’s growth journey and will drive performance excellence in the global team.”
Dayapatra has a bachelor’s degree in Electronics Engineering from IET, Lucknow, and a master’s degree in General Management from IISc, Bangalore.
About Infogain
Infogain is a human-centered digital platform engineering company based out of Silicon Valley. We engineer business outcomes for Fortune 500 companies and digital natives in the technology, healthcare, insurance, travel, telecom, and retail/CPG industries. We accelerate experience-led transformation in the delivery of digital platforms using technologies such as cloud, microservices, automation, IoT, and artificial intelligence. Infogain is a multi-cloud expert across hyperscale cloud providers – Microsoft Azure, Google Cloud Platform, and Amazon Web Services.
Infogain, an Apax Funds portfolio company, has offices in California, Washington, Texas, the UK, the UAE, and Singapore, with delivery centers in Seattle, Houston, Austin, Kraków, Noida, Bengaluru, Pune, Gurgaon, and Mumbai. To learn more, visit www.infogain.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220103005521/en/
Social Media:
https://www.facebook.com/pages/Enterprise-IT-CompanyInfogain/245846616349?ref=ts
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom